Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yervoy Launch in Europe gets clinicians excited about melanoma combo with Zelboraf

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb has begun its roll-out of the novel advanced melanoma treatment Yervoy (ipilimumab) in Europe, as Genentech and Plexxikon received their first approvals in the US for another promising treatment, Zelboraf (vemurafenib). The two drugs, which are now being tested for use in combination, are heralding a new era in the treatment of melanoma, ending a period of 30 years' stagnation in drugs for the disease.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Topics

Related Companies

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel